Targeted Therapy: Dendrimer‐Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy (Adv. Therap. 2/2021). Issue 2 (24th February 2021)

• Record Type: Journal Article
• Authors: Cho, Hongkwan; Kambhampati, Siva P.; Lai, Michael J.; Zhou, Lingli; Lee, Grace; Xie, Yangyiran; Hui, Qiaoyan; Kannan, Rangaramanujam M.; Duh, Elia J.
• Is Part Of: Advanced therapeutics. Volume 4:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-24
• Subjects: Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202170003
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract : Specific and robust targeting of pathogenic cells would represent a major advance in treatment of eye diseases including diabetic retinopathy. In article number 2000181 Rangaramanujam M. Kannan, Elia J. Duh and co‐workers use the corticosteroid triamcinolone conjugated to the surface of PAMAM‐dendrimers, which are tree‐like branching polymeric nanoparticles. This dendrimer‐triamcinolone conjugate selectively targets activated, amoeboid microglia in diseased retina, reprogramming them to quiescent ramified microglia, with resulting neuroprotective effects and suppression of pathologic retinal angiogenesis. Dendrimer‐mediated drug delivery to pathogenic microglia represents a promising therapeutic strategy with high potency and low toxicity. Image credit: Sylvia Heredia